Record Yearend Backlog of $3.5 Million for Fiscal Year 2020 Strong demand in leading markets drove a sales increase of 32.3% over fiscal 2019 to $15.3 million with gross margin of 48%, a 240 basis point improvement; For the fourth quarter, sales were up 88% over the prior-year period with… Read More..

SOUTH SAN FRANCISCO, May 28, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of its executive team will participate in a Fireside Chat during the Jefferies… Read More..

Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis Conference Call to be held Thursday, May 21, 2020 at 5:00 pm EDT Data Support Hypothesis that Tc99m Tilmanocept Imaging Can Provide Early Indicator of Treatment Response DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc.… Read More..